Hepatitis B viral mutants and their relevance to the Canadian health care system

Canadian Journal of Gastroenterology

Volumn 16, Issue 1, 2002, Pages 45-54

  Minuk, Gerald Y ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Hepatitis B virus

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; VIRUS DNA; VIRUS ENZYME;

CANADA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE MUTATION; HEALTH CARE SYSTEM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSURVEILLANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VIRUS GENOME; VIRUS MUTANT; VIRUS RESISTANCE;

EID: 0036129456     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/516172     Document Type: Review

References (106)

1. Hepatitis B: Evolving epidemiology and implications for control
2. The hepatitis B virus
3. Biology of hepatitis B virus
4. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis
5. Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles
6. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation
7. Assembly of hepadnaviral virions and subviral particles
8. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator
9. Protective potential of hepatitis B virus antigens other than the S gene protein
10. Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection
11. Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein
12. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis
13. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein
14. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia
15. Compact organization of the hepatitis B virus genome
16. Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation
17. Expression of the hepatitis B virus core gene in vitro and in vivo
18. Serologic diagnosis and acute and chronic viral hepatitis
19. Hepatitis B core particles as a universal display model: A structure-function basis for development
20. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements
21. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma
22. Activation of protooncogene c-jun by the X protein of hepatitis B virus
23. Hepatitis B virus infection
24. Two-codon insertion mutations of the HBx define two separate regions necessary for its trans-activation function
25. Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation
26. Biochemistry and functions of hepatitis B virus X protein
27. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
28. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene
29. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice
30. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome
31. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors
32. HBx protein of hepatitis B virus interacts with the C-terminal portion of a novel human proteasome alpha-subunit
33. Proteasome complex as a potential cellular target of hepatitis B virus X protein
34. Clinical implications of mutations in the heptitis B virus genome
35. Synthesis and encapsidation of duck hepatitis B virus versus reverse transcriptase do not require formation of core-polymerase fusion proteins
36. Replication strategy of human hepatitis B virus
37. Characterization of hepatitis B virus X gene: In vitro translation of mRNA from COS-1 cells transfected with the X gene
38. Hepatitis B replication - An update
39. Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: Implications for other reverse transcribing elements
40. Hepatitis B replication
41. Vaccine-induced hepatitis B surface antigen positivity in hemodialysis patients: Incidental and surveillance data
42. Serologic diagnosis of viral hepatitis
43. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B
44. Co-occurrence of hepatitis B surface antigen of a particular subtype and antibody to a heterologous subtypic specificity in the same serum
45. Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis
46. e: A third hepatitis B antigen?
47. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
48. A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
49. Viral dynamics in hepatitis B virus infection
50. Rapid evolution of RNA viruses
51. Mutation rate of the hepadnavrius genome
52. Vaccine-induced escape mutant of hepatitis B virus
53. Clinical relevance of hepatitis B viral mutations
54. The clinical significance of surface antigen variants of hepatitis B virus
55. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen
56. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by mono-clonal HBsAg ELISA
57. A unique insertion in the S gene of surface antigen-negative hepatitis B virus Chinese carriers
58. Surface gene variation of HBV: Scientific and medical relevance
59. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
60. Immunoassay detection of hepatitis B surface antigen mutants
61. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus
62. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant
63. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA
64. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis
65. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
66. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal
67. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage
68. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong
69. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
70. Clinical relevance of mutations in the precore genome of the hepatitis B virus
71. Identification of HBV variants which cannot produce precore-derived HBeAg and may be responsible for severe hepatitis
72. Pre-core mutant infections in the Canadian Inuit
73. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B
74. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany
75. Hepatitis B virus mutants
76. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation
77. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China
78. High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers
79. Analysis of the precore and core promoter DNA sequence in liver tissues from patients with hepatocellular carcinoma
80. The precore/core promoter mutation of hepatitis B virus: Clinical significance and an easy method of detection
81. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion
82. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation
83. Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation
84. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunophrophylaxis
85. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
86. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance
87. Genomic variations in the hepatitis B core gene: A possible factor influencing response to interferon alfa treatment
88. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
89. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group
90. Identification of major hepatitis B core antigen determinant by using synthetic peptides and monoclonal antibodies
91. Precore mutations and core clustering mutations in chronic hepatitis B virus infection
92. High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection
93. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection
94. Specific deletions in the hepatitis B virus core open reading frame in patients with chronic active hepatitis B
95. Naturally occurring hepatitis B virus core gene mutations
96. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
97. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
98. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation
99. A one-year trial of lamivudine for chronic hepatitis B
100. Lamivudine as initial treatment for chronic hepatitis B in the United States
101. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
102. Therapy with nucleoside analogues for hepatitis B virus infection
103. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
104. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
105. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx
106. Detection of hepatitis B surface antigen mutants and their integration in human hepatocellular carcinoma